anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Catheter ablation of atrial fibrillation (AF) is an established therapy that reduces AF burden, improves quality of life, and reduces the risks of cardiovascular outcomes. Although there are clear guidelines for the application of de novo catheter ablation, there is less evidence to guide recommendations for repeat catheter ablation in patients who experience recurrent AF. In this review, we examine the rationale for repeat ablation, mechanisms of recurrence, patient selection, optimal timing, and procedural strategies. We discuss additional important considerations, including treatment of comorbidities and risk factors, risk of complications, and effectiveness. Mechanisms of recurrent AF are often due to non-pulmonary vein (non-PV) triggers; however, there is insufficient evidence supporting the routine use of empiric lesion sets during repeat ablation. The emergence of pulsed field ablation may alter the safety and effectiveness of de novo and repeat ablation. Extrapolation of data from randomized trials of de novo ablation does not optimally inform efficacy in cases of redo ablation. Additional large, randomized controlled trials are needed to address important clinical questions regarding procedural strategies and timing of repeat ablation.
The invention discloses a medicine for treating cold and cough and a preparation method thereof. The medicine comprises herb of passionflower, litchi leaves at the bottoms of ponds, gallbladders of carps, nails, fruit of towel gourd, blood of crocodiles, herb of creeping waterprimrose, amphibious crab, common bombax flower, kudzuvine root, peel of sweet orange, Chinese crickets, sterculia nobililis and longan mistletoe. The preparation method comprises the following steps: weighing the components according to the parts by weight; grinding the nails into powder, drying the amphibious crab and the Chinese crickets in the sun and putting the processed components in a pot together to be stir-fried with big fire for 2-5 minutes for later use; adding other components except the gallbladders of carps to the pot in the step B and adding water 10-20 times the components to decoct the components for 20-120 minutes; adding the bile of the gallbladders of carps to the step C, thus obtaining the medicine. The invention aims to provide the medicine for treating cold and cough to overcome the defects in the prior art. The medicine is reasonable in proportion and has quick curative effects. The invention also aims to provide the method for preparing the medicine for treating cold and cough.
This is an Observational, retrospective study on the use of Risperidone long-acting injectable. The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone. Patient outcomes will be evaluated based on pre-existing risk or disease factors and past medication use. Data will be collected from medical charts and other available medical records from one year prior to risperidone treatment until discontinuation of risperidone long acting injectable. The study will compare the number of days hospitalized for reasons relating to psychosis before and after treatment with risperidone long-acting injectable. Information about past use of anti-psychotic medications will be collected. The occurrence and frequency of adverse events \[Extra-Pyramidal Symptoms (EPS) - the abnormal body movements sometimes associated with antipsychotic medications, body weight changes, drowsiness, sexual problems\] and the dose or change in dose of Risperidone long-acting injectable will also be collected. The study will also investigate the relapse rate and the hospitalization rate before and after treatment. It is a chart review type of study. No study drug has been used in the study.
Men with localized prostate cancer (PCa) with small tumor burden may be followed on active surveillance (AS) rather than active treatment. AS is an attempt to avoid over-treatment of PCa, which is estimated to be insignificant at the time of diagnosis, and therefore unlikely to affect patient morbidity and mortality. AS include close monitoring with PSA measurement (blood test), digital rectal exploration (DRE) and trans-rectal ultrasound-guided prostate biopsy (TRUS-bx) at regular intervals, so that active treatment can be initiated if the cancer becomes more aggressive. It is crucial that patients undergoing AS are staged correctly, to avoid underestimating more aggressive disease and patients mistakenly are enrolled into AS instead of active treatment.

Previously, a PhD study conducted at Herlev Hospital revealed that multiparametric MRI (mp-MRI) of the prostate can improve the detection and staging of PCa and may add additional information about tumor aggressiveness compared to the traditional methods DRE and TRUS-bx. Mp-MRI at the inclusion of AS may detect missed significant tumors and potential areas of higher aggressiveness than detected by the traditional biopsies. Additional targeted biopsies from these suspicious areas can then be performed with a re-evaluation of the treatment plan, if more advanced disease is identified. Conversely, mp-MRI has a high negative predicted value for significant disease and can be used to rule out significant PCa, reassuring patients and physicians to go on with AS. Mp-MRI has been used at the Urology Department, Herlev Hospital, since 2013 in the diagnosis of PCa and in the evaluation of patients undergoing AS. The main objective of this study is to retrospectively investigate, whether mp-MRI can improve the selection of patients suitable for Active Surveillance and have a relevance in the ongoing monitoring.
Statins, also known as HMG-CoA reductase inhibitors, are widely prescribed drugs for the prevention and treatment of cardiovascular diseases. In addition to their lipid-lowering effects, these compounds have been found to possess immune-modulating properties. Macrophages, which are crucial phagocytic cells in the body, can be divided into two main subsets: M1 (proinflammatory) and M2 (anti-inflammatory). While there is evidence suggesting that statins exert an anti-inflammatory action on macrophages and promote their polarization towards the M2 subset, recent studies have identified the proinflammatory impact of statins on macrophages, leading to polarization towards the M1 subset. For example, statins have been shown to inhibit NF-κB activation to promote anti-inflammatory responses. On the other hand, statins can induce NFκB/AP-1 activation and increase IL-1β secretion in macrophages to promote pro-inflammatory responses. This review aims to provide a comprehensive overview of both in vivo and in vitro studies that have investigated the effects of statins on macrophage polarization and inflammatory responses in various diseases. Furthermore, this review seeks to evaluate the underlying mechanisms involved in these effects. By summarizing the existing evidence, this review contributes to our understanding of the complex interactions between statins and macrophages in different disease contexts.
This is the experimental group. Exercise is prescribed for 150 min/week. Due to COVID-19 restrictions the exercise supervision was allowed to be either remotely or in the context of a laboratory setting.
BACKGROUND: Current research on delayed gastric emptying (DGE) after pancreatic surgery is predominantly focused on pancreaticoduodenectomy (PD), with little exploration into DGE following total pancreatectomy (TP). This study aims to investigate the risk factors for DGE after TP and develop a predictive model.
METHODS: This retrospective cohort study included 106 consecutive cases of TP performed between January 2013 and December 2023 at Peking Union Medical College Hospital (PUMCH). After applying the inclusion criteria, 96 cases were selected for analysis. These patients were randomly divided into a training set (n = 67) and a validation set (n = 29) in a 7:3 ratio. LASSO regression and multivariate logistic regression analyses were used to identify factors associated with clinically relevant DGE (grades B/C) and to construct a predictive nomogram. The ROC curve, calibration curve, decision curve analysis (DCA), and clinical impact curve (CIC) were employed to evaluate the model's prediction accuracy.
RESULTS: The predictive model identified end-to-side gastrointestinal anastomosis, intraoperative blood transfusion, and venous reconstruction as risk factors for clinically relevant DGE after TP. The ROC was 0.853 (95%CI 0.681-0.900) in the training set and 0.789 (95%CI 0.727-0.857) in the validation set. The calibration curve, DCA, and CIC confirmed the accuracy and practicality of the nomogram.
CONCLUSION: We developed a novel predictive model that accurately identifies potential risk factors associated with clinically relevant DGE in patients undergoing TP.
Physical activity (PA) is a major component of the management of patients with cystic fibrosis (CF). Regular PA is associated, in cystic fibrosis as in other pathologies, with health benefits and a greater life expectancy. However, the literature shows an absence of consensus for the daily PA level reached by CF patients, and also for the determinants of this PA level. It appears that CF patients tend to have a reduced PA level, compared to international guidelines. Some determinants have already been mentioned, like physical, psychological or organizational factors. But these factors have not been considered in a multifactorial way, by also considering social and environmental factors, and are rarely associated with objective PA level measurement or only reported in paediatric population. A better comprehension of these determinants of daily PA level represents an important issue for the optimization of interventions designed for the promotion of PA in cystic fibrosis.

For this study, a population of CF patients will realize an evaluation of their daily PA level based on accelerometry (by wearing a portable device over 7 days). During the PA assessment, patients will have a questionnaire to fill in, delivered with the sensor. The objective assessment of PA level will be analyzed with regard to various parameters from different dimensions: individual, clinical, psycho-social and environmental. Individual and clinical parameters will be collected from patients' data routinely assessed for the management of patients. Psycho-social and environmental parameters will be assessed with a specific questionnaire, specifically designed from 3 different questionnaires.
FIELD: organic chemistry, medicine. SUBSTANCE: invention relates to composition containing therapeutically effective amount of epoxysteroid aldosterone receptor antagonist and therapeutically effective amount of angitensin-II receptor antagonist. Composition can be used in medicine for treatment of circulation disorder including cardiovascular damages, for example, hypertension, congested cardiac insufficiency, cirrhosis and ascite. Compounds showing high activity and biological availability are preferable as an antagonists of angiotensin-II receptors. These compounds have residue of imidazole or triazole connected to diphenylmethyl or pyridinyl/phenylmethyl radical. Preferable epoxysteroid antagonists of aldosterone receptors are 20-spiroxane steroid compounds having 9α, 11α-substituted epoxy-group. Preferably, the composition has 5-[2-[5-[(3,5-dibutyl-1H-1,2,4-triazole-1-yl)- methyl] -2-pyridinyl] -phenyl-1H- tetrazole as antagonist of angiotensin-II receptors and epoxymexrenone as antagonist of aldosterone receptors. Use of invention ensures to attenuate hypertension and decrease or prevent progression of congested cardiac insufficiency simultaneously. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 11 cl, 5 tbl
Hypernatremia is defined as serum sodium (sNa) levels above 145 mmol/L and is caused by abnormalities in water balance, mainly in children, elderly, and critically ill patients. It occurs in 3% of hospitalized patients and in 9% of critically ill patients. Hypernatremia indicates hypertonic hyperosmolality and causes water outflow, resulting in cell dehydration. Most of the symptoms and signs of hypernatremia are due to brain abnormalities, which can progress to hyperventilation, muscle weakness, consciousness (lethargy), and coma. The short-term mortality rate of hypernatremia is 50%-60%. Decreased osmotic pressure in the extracellular fluid during correction of hyponatremia can cause cellular edema and permanent brain damage. The recommended sNa correction rate for acute hypernatremia is up to 1 mmol/L/h, whereas that for chronic hypernatremia is less than 0.5 mmol/L/h (approximately 10 mmol/L/day). However, these correction rates have only been studied and proven in pediatric patients. A recent study conducted on adults revealed that rapid correction (more than 0.5 mmol/L/h) was not associated with a higher risk for mortality, seizures, and alteration of consciousness. Several studies reported that excessively slow rates of sNa correction were associated with higher mortality, whereas rapid rates demonstrated lower mortality. There are no established guidelines for the Na correction rate for hypernatremia. The European and American guidelines recommend infusion of electrolyte-free water (10 mL/kg over 1 h or 3 mL/kg/h) for the management of overcorrection of hyponatremia. In the previously published SALSA I trial, 10 mL/kg over 1 h was applied as a method of re-lowering treatment in overly rapid correction of hyponatremia. However, this rapid intermittent bolus of electrolyte-free water has never been applied to treat hypernatremia.

The aim of this prospective, randomized, open-labeled, multi-center, and investigator-initiated trial is to determine whether a rapid and intermittent bolus of electrolyte-free water in hypernatremia can increase the incidence of rapid decrease in sNa level and increase the survival time compared to the slow continuous administration method. A total of 166 patients with severe hypernatremia will be enrolled and randomly assigned to receive either intermittent bolus or slow continuous infusion of 5% dextrose water. The participants will be divided into three groups according to age and sex and will receive 5% dextrose water for 2 days at different correction rates. Serum sodium will be measured every 3 h from the beginning to 6 h, followed by every 6 h until 48 h. In addition, urine sodium and potassium levels will be measured at baseline and 24 h. The PP (Per Protocol) analysis will be applied to enrolled participants who is infused with 75-125% of total planned volume of 5% dextrose water.
SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
PURPOSE:To obtain a dermal agent for external use, capable of improving the skin state of an atopic dermatitis patient by using squalene or/and squalene in combination with glycerin and/or erythritol. CONSTITUTION:This dermal agent for external use is prepared by using (a) squalane or/and squalene in combination with (b) glycerin and/or erythritol. The amount of the component (a) is preferably equal to or more than that of the component (b) and the amount of the component (b) is especially preferably >=8wt.%. The other hand, the content of the component (a) is preferably >=50wt.% based on the oil components. Hyaluronic acid or its salt is recommendably further added to this composition in an amount of >=0.001wt.%. This dermal agent for external use can improve roughness of the skin and prevent the skin from drying. This dermal agent is effective especially for therapy of xeroderma and ichthyosis which occur frequently in an atopic dermatitis patient. The effect for improving roughness of the skin or preventing the skin from drying can be improved by adding hyaluronic acid or its salt to the dermal agent of external use.
PROBLEM TO BE SOLVED: To provide a heating element which contributes to the embodiment of a higher line speed, the extreme improvement in productivity, the simplification of production equipment and the saving of energy by sealing a base material and a coating material with a tacky adhesive layer, is free from thermal deterioration at the time of joining of the base material and the coating material, has particularly the high softness of the sealed part, has the high fitting property to the body surface and follow-up characteristic to the movements of the body surface as a result of the greatly improved softness of the entire part, has the greatly improved feel of use and eliminates stresses. SOLUTION: This heating element consists of the film- or sheet-like base material 3, an exothermic compsn. layer 2 laminated on the base material 3, the film- or sheet-like coating material 4 for coating the base material 3 and the exothermic compsn. layer 2 from above and the tacky adhesive layer 5 laminated on at least the peripheral edge on the base material 3 and/or the peripheral edge of the rear surface of the coating material 4. At least either of the base material 3 and the coating material 4 has air permeability. The peripheral edges of the base material 3 and the coating material 4 are sealed with the tacky adhesive layer 5 having elongation property.
The invention relates to the technical field of medicines, and relates to an oral instant film agent and a preparation method thereof. The oral instant film agent comprises the following components: the content of the preparation is calculated according to the added solvent, namely purified water. The medicine, the film forming material, the plasticizer, the flavoring agent and the pigment are dissolved in 100ml of purified water together to obtain a film forming solution. Per 100ml of purified water contains: 0.07-0.3g of medicine, 13.6-25g of film forming material, 0.9-9.4g of plasticizer, 0-0.4g of flavoring agent and 0-0.012g of pigment. The mass ratio of the film forming material to the plasticizer is 15:1-15: 7. The film forming material is a combination of HPMC-E5 and PVA588, and the mass ratio of the HPMC-E5 to the PVA588 is 3:1-4: 1; the plasticizer is a combination of PEG400 and glycerol, and when the ratio of the PEG400 to the glycerol is 3:1-1:2, the disintegration time of the medicine is shortest and is less than 10s, and the medicine can be completely dissolved within 5 min. The compliance and the safety of the medicine taking of the old and the infant patients are improved.
<P>PROBLEM TO BE SOLVED: To provide a method for producing biologically active human α-galactosidase A (α-GalA).  <P>SOLUTION: The method for mass-producing the human α-GalA comprises cloning an α-GalA cording sequence on eukaryotic host cell expressing system and expressing thereon. The eukaryotic host cell expressing system, especially, a mammal host cell expression system provides a translation and simultaneous modification required for proper processing (e.g. glycosylation, phosphorylation and the like) and selection of expression products and thereby an active enzyme is produced. By the method, a recombinant α-GalA is secreted from the host cell produced by genetic engineering and collected from a culture medium at a good yield. The produced α-GalA is unrestrictively applied to, in treatment of Fabry's disease, hydrolysis of α-galactosyl residue in glycoconjugate and/or transformation of blood group antigen B on erythrocyte to blood group antigen O.  <P>COPYRIGHT: (C)2004,JPO
Provided are therapeutic products in a form of individual doses for consumption by users. A therapeutic product includes a therapeutic portion and a package. The therapeutic portion includes one or more parts of a plant and may be compressed and formed into an individual dose. The therapeutic product further includes a fibrous portion that includes one or more further parts of the plant. The fibrous portion is structurally attached to the therapeutic portion to form the individual dose of the therapeutic product. The package accommodates the therapeutic portion and the fibrous portion acting as a structural substrate, or the therapeutic portion alone without the fibrous portion.
Gestational diabetes is characterized by hyperglycaemia diagnosed during pregnancy. Gestational and pregestational diabetes can have deleterious effects during pregnancy and perinatally. The baby's weight is frequently above average and might reach macrosomia (≥ 4 kg), which can reduce pregnancy time causing preterm births, and increase foetal-pelvic disproportion which often requires delivery by caesarean section. Foetal-pelvic disproportion due to the baby's weight can also cause foetal distress resulting in lower Apgar scores. To analyse the association between pregestational and gestational diabetes with maternal and foetal risk. We conducted a retrospective cohort study in women pregnant between 2012 and 2018 in the region of Lleida. Regression coefficients and 95% confidence intervals (CI) were used. The multivariate analysis showed statistically significant associations between pregestational diabetes and: prematurity (OR 2.4); caesarean section (OR 1.4); moderate (OR 1.3), high (OR 3.3) and very high (OR 1.7) risk pregnancies; and birth weight ≥ 4000 g (macrosomia) (OR 1.7). In getational diabetes the multivariate analysis show significant association with: caesarean section (OR 1.5); moderate (OR 1.7), high (OR 1.7) and very high (OR 1.8) risk pregnancies and lower 1-minuto Apgar score (OR 1.5). Pregestational and gestational diabetes increase: pregnancy risk, caesarean sections, prematurity, low Apgar scores, and macrosomia.
In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a  Homo sapiens  epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45,  S. cerevisiae , homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.